Recruiting NA INTERVENTIONAL 3-arm NCT07093463

Colon-delivered Riboflavin and Gut Microbiota Composition (CONCOL)

The Benefit of Colon-delivered Riboflavin (Riboflavin-cd) vs. Conventional Riboflavin on Gut Microbiota Composition and Metabolic Output in Healthy Aging Subjects - a Pilot Proof of Concept Study

Sponsor: Analyze & Realize

Conditions Gut Health Microbiome Dysbiosis

Interventions Colon-delivered riboflavin Conventional riboflavin Microcrystalline Cellulose

Updated 3 times since 2025 Last updated: Aug 13, 2025 Started: Jul 18, 2025 Primary completion: Dec 20, 2025 Completion: Mar 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07093463, this NA trial focuses on Gut Health and Microbiome Dysbiosis and remains actively recruiting participants. Sponsored by Analyze & Realize, it has been updated 3 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Mar 2026 — Present [monthly]

Recruiting NA
Sep 2025 — Mar 2026 [monthly]

Recruiting NA
Aug 2025 — Sep 2025 [monthly]

Recruiting NA

First recorded

Jul 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Analyze & Realize
dsm-firmenich Switzerland AG

Data source: dsm-firmenich Switzerland AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany